What is claimed is:
1. A method in a data processing system for generating a metadata stream, the method comprising the data processing system implemented step of: receiving calls from an application, wherein the calls are received calls; tracking current application attributes in the received calls; identifying a new section call in the received calls; placing the new section call within the metadata stream to identify a new section in the metadata stream; and placing current application attributes in the metadata stream within the new section identified by the new section call, wherein the new section within the metadata stream may be printed using the current application attributes located within new section.
2. The method of claim 1, wherein the new section is located between the new section call for the new section and a new section call for a section immediately following the new section.
3. The method of claim 1, wherein the new section call is a new page call and wherein the new section is a new page.
4. A method in a data processing system for generating a metadata stream, the method comprising the data processing system implemented steps of: receiving an attribute call to set an attribute; querying a first group of attributes to determine whether the attribute call is present in the first group of attributes; updating the first group of attributes in response to the attribute call being absent in the first group of attributes; receiving a primitive call; erasing all attribute calls stored in a second group of attributes in response to the primitive call being a call for a new section; retrieving an attribute call associated with the primitive from the first group of attributes; determining whether the attribute call associated with the primitive is present in a second group of attributes; updating the second group of attributes to include the attribute call associated with the primitive call in response to the attribute call associated with the primitive call being absent in the second group of attributes; placing the attribute call associated with the primitive call in the metadata stream in response to updating the second group of attributes; and placing the primitive call in the metadata stream.
5. The method of claim 1, wherein the first group of attributes is located in a current application attributes database.
6. The method of claim 1, wherein the second group of attributes is located in a current metadata attributes database.
7. The method of claim 1 further comprising: storing the metadata stream in a storage device.
8. The method of claim 1 further comprising: sending the metadata stream to an output device.
9. The method of claim 8, wherein the output device is a printer.
10. The method of claim 1, where in the first group of attributes and the second group of attributes are located in a data structure.
11. The method of claim 10, wherein the data structure is located in a random access memory.
12. The method of claim 1, wherein the first group of attributes is located in a first database and the second group of attributes are located in a second database.
13. A method in a data processing system for processing a metadata stream, the method comprising the data processing system implemented steps of: receiving a metadata stream from a first process, wherein the metadata stream includes a document with a plurality of sections; tracking format data describing a format of the document in the metadata stream to identify current format data in metadata stream; and responsive to a new section in the metadata stream, placing current format data within the metadata stream for the new section such that all format data describing the new section is located within the new section in the metadata stream.
14. The method of claim 13 further comprising: responsive to a new command to print a selected section of the metadata stream, locating the selected section of the metadata stream and printing the selected section using current format data within the selected section; and printing the selected section using the current format data within the selected section.
15. The method of claim 14, wherein the printing step prints to a file.
16. The method of claim 14, wherein the printing step prints to a printer.
17. The method of claim 13, wherein the plurality of sections is a plurality of frames.
18. The method claim 13, wherein the plurality of sections is a plurality of pages.
19. The method of claim 18, wherein a beginning of a page within the plurality of pages is identified within the metadata stream by a new page call.
20. A data processing system for generating a metadata stream, the data processing system comprising: reception means for receiving calls from an application, wherein the calls are received calls; tracking means for tracking current application attributes in the received calls; identification means for identifying a new section call in the received calls; first placement means for placing the new section call within the metadata stream to identify a new section in the metadata stream; and second placement means for placing current application attributes in the metadata stream within the new section identified by the new section call, wherein the new section within the metadata stream may be printed using the current application attributes located within new section.
21. The data processing system of claim 20, wherein the new section is located between the new section call for the new section and a new section call for a section immediately following the new section.
22. The data processing system of claim 20, wherein the new section call is a new page call and wherein the new section is a new page.
23. A data processing system for generating a metadata stream, the data processing system comprising: first reception means for receiving an attribute call to set an attribute; first querying means for querying a first group of attributes to determine whether the attribute call is present in the first group of attributes; first updating means for updating the first group of attributes in response to the attribute call being absent in the first group of attributes; second reception means for receiving a primitive call; erasing means for erasing all attribute calls stored in a second group of attributes in response to the primitive call being a call for a new section; retrieving means for retrieving an attribute call associated with the primitive from the first group of attributes; determination means for determining whether the attribute call associated with the primitive is present in a second group of attributes; second updating means for updating the second group of attributes to include the attribute call associated with the primitive call in response to the attribute call associated with the primitive call being absent in the second group of attributes; first placing means for placing the attribute call associated with the primitive call in the metadata stream in response to updating the second group of attributes; and second placing means for placing the primitive call in the metadata stream.
24. The data processing system claim 23, wherein the first group of attributes is located in a current application attributes database.
25. The data processing system of claim 23, wherein the second group of attributes is located in a current metadata attributes database.
26. The data processing system of claim 23 further comprising: storing means for storing the metadata stream in a storage device.
27. The data processing system of claim 23 further comprising: an output device; sending means for sending the metadata stream to the output device.
28. The data processing system of claim 27, wherein the output device is a printer.
29. The data processing system of claim 23, wherein the first group of attributes and the second group of attributes are located in a data structure.
30. The data processing system of claim 29, wherein the data structure is located in a random access memory.
31. The data processing system of claim 23, wherein the first group of attributes is located in a first database and the second group of attributes is located in a second database.
32. A data processing system for processing a metadata stream, the data processing system comprising: reception means for receiving a metadata stream from a first process, wherein the metadata stream includes a document with a plurality of sections; tracking means for tracking format data describing a format of the document in the metadata stream to identify current format data in metadata stream; and placing means, responsive to a new section in the metadata stream, for placing current format data within the metadata stream for the new section such that all format data describing the new section is located within the new section in the metadata stream.
33. The data processing system of claim 32 further comprising: locating means, responsive to a new command to print a selected section of the metadata stream, for locating the selection section of the metadata stream; and printing means for printing the selected section using the current format data within the selected section.
34. The data processing system of claim 33, wherein the printing means prints to a file.
35. The data processing system of claim 33, wherein the printing means prints to a printer.
36. The data processing system of claim 32, wherein the plurality of sections is a plurality of frames.
37. The data processing system claim 32, wherein the plurality of sections is a plurality of pages.
38. The data processing system of claim 37, wherein a beginning of a page within the plurality of pages is identified within the metadata stream by a new page call.
39. A compute r pro gram product in a computer readable medium for generating a metadata stream, the computer program product comprising: first instructions for receiving calls from an application, wherein the calls are received calls; second instructions for tracking current application attributes in the received calls; third instructions for identifying a new page call in the received calls; fourth instructions for placing the new page call within the metadata stream to identify a new page in the metadata stream; and fifth instructions for placing current application attributes in the metadata stream within the new page identified by the new page call, wherein the new page within the metadata stream may be printed using the current application attributes located within new page, wherein the instructions are embodied within the computer readable medium.
40. A computer program product in a computer readable medium for processing a metadata stream, the computer program product comprising: first instructions for receiving a metadata stream from a first process, wherein the metadata stream includes a document with a plurality of sections; second instructions for tracking format data describing a format of the document in the metadata stream to identify current format data in metadata stream; and fourth instructions, responsive to a new section in the metadata stream, for placing current format data within the metadata stream for the new section such that all format data describing the new section is located within the new section in the metadata stream, wherein the instructions are embodied within the computer readable medium.
Read More..>>
7 Kasım 2008 Cuma
16 Ekim 2008 Perşembe
What is patent-worthy?
Due to differing legal standards for patentability, applications for gene patents face different outcomes in various countries
The United States Patent and Trademark Office granted four gene patents to Sagami Chemical Research Institute in Sagamihara City for human cDNAs related to liver function and cell division, although the exact function and mechanism of the coded proteins were unknown. Earlier last year, the Japanese Patent Office had rejected these applications, demonstrating, according to the Japanese business newspaper Nikkei (January 8, 2000), that the USPTO has a more relaxed stance in granting gene patents.
Indeed, it is not unusual that a patent for the same invention is granted in one country and denied in another, because the legal tests for patentability are not the same in every jurisdiction. Although inventors can file under the Patent Cooperation Treaty with most patent offices in the world to receive protection of their invention, the individual outcome still depends on the patent office in each country. Particularly when it comes to granting patents for expressed sequence tags (ESTs)—when found by sequencing or by mere homology searches in databases—the USPTO has been shown recently to decide differently from its European and Japanese counterparts.
However, a comparative statement, such as the one the Japanese newspaper made, may be too simplistic. 'Among patent practitioners, the laws of the US, Europe and Japan are considered to be the most developed in the biotech field,' S.Peter Ludwig, senior member of Darrby & Darby PC, an intellectual property law firm in New York, said, 'but they are certainly not "equivalent". In some respects Japanese law on patentability is more lenient than US law, in others, more stringent.'
International differences in intellectual property laws and their consequences for the biotech industry were among the topics of the BioJapan 2000 symposium in September last year in Tokyo. Patent attorneys and patent officers from Japan, Australia, the UK, Germany and the United States expounded about international strategies for biotech patents. Among the speakers, Janis K. Fraser of Fish & Richardson PC, an intellectual property law firm in Boston, MA, compared the criteria for patentability of genes that the US, European and Japanese patent offices apply. All three accept patent applications for chromosomal genes, cloned cDNA and virtual cDNA discovered by data mining. According to Fraser, all three patent offices ask the same questions: 'first: is the full sequence of the gene disclosed? In Europe and Japan, if only a partial sequence is disclosed, is there a straightforward way to obtain the full sequence? Secondly: is the gene novel and non-obvious? And thirdly: is a specific and plausible use for the gene or its encoded protein disclosed?'
Inconsistencies arise when patent offices make differing decisions based on the completeness of the genetic information disclosed in the application. For instance the policy of the USPTO does not now allow claims broad enough to cover a whole cDNA sequence if only a partial cDNA sequence has been disclosed, Fraser continued. In contrast she said, 'the EPO (European Patent Office) and JPO (Japanese Patent Office) consider a partial sequence adequate if it were clear that the full sequence could be obtained without undue burden.' However, the EPO and JPO are not so lenient as the USPTO on the requirement for novelty and non-obviousness, Fraser said, because of fewer case laws in these countries. In the shrinking middle ground, the EPO considers a gene non-obvious 'when neither the purified protein nor any homologous gene is catalogued in the prior art.'
As for the utility requirement, Fraser pointed out that USPTO demands a 'specific and plausible' description of the intended use of an invention to accept a patent application. For example, the intended use of proteins as shampoo ingredients or of transgenic mice as snake food would not be sufficient. 'A mere statement that a gene or protein could be used in therapy, though based on sound logic, is rarely enough to satisfy the USPTO,' she said. On this point, the utility rules of the EU and Japan are similar to the US, she added.
The differing standards for the patentability of a discovery, particularly regarding USPTO's policy, have already raised concerns and criticism. Researchers, economists and politicians fear that unfettered patenting of DNA sequences will eventually hinder research in academia as well as in the private sector. In a joint statement in March last year, President Clinton and Prime Minister Tony Blair urged private companies to 'make raw [DNA] data publicly available' and to make 'responsible use of patents.' Their statement seemed to be directed at the activities of certain private data marketing companies—such as Celera Genomics and Incyte—that have been engaged in high-volume sequencing of human DNA and collection of genes and genetic variations.
Earlier, in April 1999, the Japan Bioindustry Association offered opinions regarding the patentability of DNA fragments and strongly criticised a 1998 US patent for human kinase homologs granted to Incyte Inc. in Palo Alto, CA. 'We are worried that if patenting of this type of invention becomes common practice it will seriously affect the entire global bioindustry,' stated the industry trade group. 'We in JBA consider that applications in relation to this type of EST invention should not be patented.' However, JBA acknowledges the utility of an EST invention as a diagnostic probe 'for a specific disease where the association with the disorder is clearly established.'
The JBA opinion represents the approximately 250 member companies, which asked the JPO to consider their standpoint when discussing the matter with the US and EU, a spokesperson said. As a non-profit organisation, JBA is chartered by the Japanese Ministry of International Trade and Industry, but is independent of it. JPO is officially a part of MITI, but in terms of policy—especially day-to-day rulings on patent applications—it has substantial autonomy.
In contrast to the USPTO and the JPO, the EPO is not under the jurisdiction of any European government or the European Union. Rules are set up by the European Patent Organisation, which represents the 20 contracting states—the EU member states as well as Switzerland, Monaco, Turkey, Cyprus and Liechtenstein. Although independent of the EU, the EPO has largely adopted its guidelines for patenting in the biotechnology sector, which puts restrictions on the patenting of ESTs similar to the guidelines that the JPO follows.
'To my knowledge, the USPTO is the only major patent office that has issued patents where the principal claims focus on the ESTs themselves,' Robert Kneller, Professor at the Intellectual Property Research Center for Advanced Science and Technology at the University of Tokyo said. 'The official position of the USPTO is that EST claims should not be treated differently from other claims. Representatives of the EPO have made statements suggesting that the EPO does not believe that claims focused on ESTs are acceptable.' JPO has also stated that the likelihood of accepting EST claims is low. 'Nevertheless, I suspect that JPO agrees with [the JBA opinion] that if ESTs have a clear diagnostic utility and are part of an inventive process, patents claiming those ESTs for such a use could be issued,' Kneller said.
However, it is unlikely that the JBA's criticism will affect the USPTO's policy on granting patents for genes. 'I do not think the JBA opinion by itself will affect the USPTO,' Kneller said, 'and it certainly will not stop applicants from filing EST-based claims with the USPTO if they think there is a reasonable chance that the USPTO will grant patents.' On the other hand, there has been a steady drumbeat of criticism from other countries as well as from companies from the US, expressing concern that the USPTO's thresholds for finding utility and non-obviousness are too low, and that the patents it issues—in particular the Incyte kinase patent—are too broad. 'The USPTO is sensitive to these criticisms and has tightened up its utility and enablement requirements,' Kneller described recent changes in the USPTO's policy. 'It is also seeking input from the scientific community as to what is obvious and predictable in the field of genome science.'
Indeed, changes are already underway. Ludwig cites a recent decision by the Court of Appeals for the Federal Circuit in Washington, DC (the court of appeal for all patent cases in the US) that elaborated the standard for compliance with the written description requirement of US Patent Law. To comply, a patent specification must include sufficient information to establish that the inventor is in possession of the claimed invention. 'To my knowledge there is no counterpart to this requirement in the patent law of most developed countries,' Ludwig said, 'in this sense, US patent law is more stringent than the laws in these other countries.'
One of the newest changes to patent law is that the USPTO has shortened the publication time for patent applications to 18 months. Shannon Mrksich of Brinks Hofer Gilson & Lione, a patent law firm in Chicago, expects that the November rule change will not be likely to accelerate academic research, but that industry will 'be reading the patents like nuts to see what competitors are up to, because lead time in development is everything.' On the other hand, she thinks that no company would refrain from filing a patent application with the USPTO to avoid this potential competitive risk.
Read More..>>
The United States Patent and Trademark Office granted four gene patents to Sagami Chemical Research Institute in Sagamihara City for human cDNAs related to liver function and cell division, although the exact function and mechanism of the coded proteins were unknown. Earlier last year, the Japanese Patent Office had rejected these applications, demonstrating, according to the Japanese business newspaper Nikkei (January 8, 2000), that the USPTO has a more relaxed stance in granting gene patents.
Indeed, it is not unusual that a patent for the same invention is granted in one country and denied in another, because the legal tests for patentability are not the same in every jurisdiction. Although inventors can file under the Patent Cooperation Treaty with most patent offices in the world to receive protection of their invention, the individual outcome still depends on the patent office in each country. Particularly when it comes to granting patents for expressed sequence tags (ESTs)—when found by sequencing or by mere homology searches in databases—the USPTO has been shown recently to decide differently from its European and Japanese counterparts.
However, a comparative statement, such as the one the Japanese newspaper made, may be too simplistic. 'Among patent practitioners, the laws of the US, Europe and Japan are considered to be the most developed in the biotech field,' S.Peter Ludwig, senior member of Darrby & Darby PC, an intellectual property law firm in New York, said, 'but they are certainly not "equivalent". In some respects Japanese law on patentability is more lenient than US law, in others, more stringent.'
International differences in intellectual property laws and their consequences for the biotech industry were among the topics of the BioJapan 2000 symposium in September last year in Tokyo. Patent attorneys and patent officers from Japan, Australia, the UK, Germany and the United States expounded about international strategies for biotech patents. Among the speakers, Janis K. Fraser of Fish & Richardson PC, an intellectual property law firm in Boston, MA, compared the criteria for patentability of genes that the US, European and Japanese patent offices apply. All three accept patent applications for chromosomal genes, cloned cDNA and virtual cDNA discovered by data mining. According to Fraser, all three patent offices ask the same questions: 'first: is the full sequence of the gene disclosed? In Europe and Japan, if only a partial sequence is disclosed, is there a straightforward way to obtain the full sequence? Secondly: is the gene novel and non-obvious? And thirdly: is a specific and plausible use for the gene or its encoded protein disclosed?'
 |
|
|
| It is not unusual that a patent for the same invention is granted in one country and denied in another, because the legal tests for patentability are not the same in every jurisdiction |
|
|
|
Inconsistencies arise when patent offices make differing decisions based on the completeness of the genetic information disclosed in the application. For instance the policy of the USPTO does not now allow claims broad enough to cover a whole cDNA sequence if only a partial cDNA sequence has been disclosed, Fraser continued. In contrast she said, 'the EPO (European Patent Office) and JPO (Japanese Patent Office) consider a partial sequence adequate if it were clear that the full sequence could be obtained without undue burden.' However, the EPO and JPO are not so lenient as the USPTO on the requirement for novelty and non-obviousness, Fraser said, because of fewer case laws in these countries. In the shrinking middle ground, the EPO considers a gene non-obvious 'when neither the purified protein nor any homologous gene is catalogued in the prior art.'
As for the utility requirement, Fraser pointed out that USPTO demands a 'specific and plausible' description of the intended use of an invention to accept a patent application. For example, the intended use of proteins as shampoo ingredients or of transgenic mice as snake food would not be sufficient. 'A mere statement that a gene or protein could be used in therapy, though based on sound logic, is rarely enough to satisfy the USPTO,' she said. On this point, the utility rules of the EU and Japan are similar to the US, she added.
The differing standards for the patentability of a discovery, particularly regarding USPTO's policy, have already raised concerns and criticism. Researchers, economists and politicians fear that unfettered patenting of DNA sequences will eventually hinder research in academia as well as in the private sector. In a joint statement in March last year, President Clinton and Prime Minister Tony Blair urged private companies to 'make raw [DNA] data publicly available' and to make 'responsible use of patents.' Their statement seemed to be directed at the activities of certain private data marketing companies—such as Celera Genomics and Incyte—that have been engaged in high-volume sequencing of human DNA and collection of genes and genetic variations.
Earlier, in April 1999, the Japan Bioindustry Association offered opinions regarding the patentability of DNA fragments and strongly criticised a 1998 US patent for human kinase homologs granted to Incyte Inc. in Palo Alto, CA. 'We are worried that if patenting of this type of invention becomes common practice it will seriously affect the entire global bioindustry,' stated the industry trade group. 'We in JBA consider that applications in relation to this type of EST invention should not be patented.' However, JBA acknowledges the utility of an EST invention as a diagnostic probe 'for a specific disease where the association with the disorder is clearly established.'
|
|
|
| There has been a steady drumbeat of criticism from other countries, as well as from companies from the US, expressing concern that the USPTO's thresholds for finding utility and non-obviousness are too low, and that the patents it issues are too broad |
|
|
|
The JBA opinion represents the approximately 250 member companies, which asked the JPO to consider their standpoint when discussing the matter with the US and EU, a spokesperson said. As a non-profit organisation, JBA is chartered by the Japanese Ministry of International Trade and Industry, but is independent of it. JPO is officially a part of MITI, but in terms of policy—especially day-to-day rulings on patent applications—it has substantial autonomy.
In contrast to the USPTO and the JPO, the EPO is not under the jurisdiction of any European government or the European Union. Rules are set up by the European Patent Organisation, which represents the 20 contracting states—the EU member states as well as Switzerland, Monaco, Turkey, Cyprus and Liechtenstein. Although independent of the EU, the EPO has largely adopted its guidelines for patenting in the biotechnology sector, which puts restrictions on the patenting of ESTs similar to the guidelines that the JPO follows.
'To my knowledge, the USPTO is the only major patent office that has issued patents where the principal claims focus on the ESTs themselves,' Robert Kneller, Professor at the Intellectual Property Research Center for Advanced Science and Technology at the University of Tokyo said. 'The official position of the USPTO is that EST claims should not be treated differently from other claims. Representatives of the EPO have made statements suggesting that the EPO does not believe that claims focused on ESTs are acceptable.' JPO has also stated that the likelihood of accepting EST claims is low. 'Nevertheless, I suspect that JPO agrees with [the JBA opinion] that if ESTs have a clear diagnostic utility and are part of an inventive process, patents claiming those ESTs for such a use could be issued,' Kneller said.
However, it is unlikely that the JBA's criticism will affect the USPTO's policy on granting patents for genes. 'I do not think the JBA opinion by itself will affect the USPTO,' Kneller said, 'and it certainly will not stop applicants from filing EST-based claims with the USPTO if they think there is a reasonable chance that the USPTO will grant patents.' On the other hand, there has been a steady drumbeat of criticism from other countries as well as from companies from the US, expressing concern that the USPTO's thresholds for finding utility and non-obviousness are too low, and that the patents it issues—in particular the Incyte kinase patent—are too broad. 'The USPTO is sensitive to these criticisms and has tightened up its utility and enablement requirements,' Kneller described recent changes in the USPTO's policy. 'It is also seeking input from the scientific community as to what is obvious and predictable in the field of genome science.'
Indeed, changes are already underway. Ludwig cites a recent decision by the Court of Appeals for the Federal Circuit in Washington, DC (the court of appeal for all patent cases in the US) that elaborated the standard for compliance with the written description requirement of US Patent Law. To comply, a patent specification must include sufficient information to establish that the inventor is in possession of the claimed invention. 'To my knowledge there is no counterpart to this requirement in the patent law of most developed countries,' Ludwig said, 'in this sense, US patent law is more stringent than the laws in these other countries.'
One of the newest changes to patent law is that the USPTO has shortened the publication time for patent applications to 18 months. Shannon Mrksich of Brinks Hofer Gilson & Lione, a patent law firm in Chicago, expects that the November rule change will not be likely to accelerate academic research, but that industry will 'be reading the patents like nuts to see what competitors are up to, because lead time in development is everything.' On the other hand, she thinks that no company would refrain from filing a patent application with the USPTO to avoid this potential competitive risk.
Read More..>>
Kaydol:
Kayıtlar (Atom)